MA5

Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - MA5

MA5 Details
Status: Closed
Activation Date: 1989DEC01
Closing Date: 1993JUL30
Phase: III

Description: Cooperative Clinical Trial of Intensive CEF versus Standard CMF as Adjuvant Therapy for Breast Carcinoma in Premenopausal Patients With Histologically Involved Axillary Nodes

Primary Publication Show

Other Publications Show

Year: 2002
Title: Prognostic and predictive value of HER2/neu in a randomized trial comparing CMF to CEF in premenopausal women with axillary lymph node postive breast cancer (NCIC CTG MA.5)
Authors: Pritchard KI;O'Malley FP;Andrulis I;Shepherd LE;Tu D;Levine MN;Bramwell VH;
Reference: Proceedings of the American Society of Clinical Oncology 2002 May 18; 21 (Part 1, abstr 165)
Link: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=16&abstractID=165

Year: 2003
Title: Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: A report from the National Cancer Institute of Canada Clinical Trials Group
Authors: Crump M;Tu D;Shepherd L;Levine M;Bramwell V;Pritchard K;
Reference: Journal of Clinical Oncology 2003 Aug 15; 21 (16)
Link:

Year: 2005
Title: The importance of temporal effects in evaluating the prognostic impact of joint ERPR expression in premenopausal women with node-positive breast cancer
Authors: Ouyang Y;Li D;Pater JL;Levine M;
Reference: Breast Cancer Research and Treatment 2005 Jul ; 92 (2)
Link:

Year: 2005
Title: Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group study - NCIC CTG MA.5
Authors: Parulekar WR;Day AG;Ottaway JA;Shepherd LE;Trudeau ME;Bramwell V;Levine M;Pritchard KI;
Reference: Journal of Clinical Oncology 2005 Sep 1 ; 23 (25)
Link:

Year: 2006
Title: Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5)
Authors: O'Malley FP;Chia S;Tu D;Shepherd LE;Levine MN;Huntsman D;Bramwell VH;Andrulis I;Pritchard KI;
Reference: Breast Cancer Research and Treatment 2006 Dec 14; 100 (Suppl 1, abstr 38)
Link:

Year: 2006
Title: Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5)
Authors: O'Malley FP;Chia S;Tu D;Shepherd LE;Levine MN;Huntsman DG;Bramwell VH;Andrulis IL;Pritchard KI;
Reference: Journal of Clinical Oncology 2006 Jun 2 ; 24 (18s Part 1, abstr 533)
Link: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=31375

Year: 2006
Title: HER2 and responsiveness of breast cancer to adjuvant chemotherapy
Authors: Pritchard KI;Shepherd LE;O'Malley FP;Andrulis IL;Tu D;Bramwell VH;Levine MN;
Reference: New England Journal of Medicine 2006 May 18; 354 (20)
Link:

Year: 2008
Title: Chromosome 17 polysomy: a unifying hypothesis underlying benefit from adjuvant anthracyclines?
Authors: Bartlett JMS;Desmedt C;Munro A;O'Malley FP;Larsimont D;di Leo A;Cameron DA;Isola J;Shepherd L;Twelves CJ;Pritchard KI;
Reference: Cancer Research 2008 Dec 11; 69 (Suppl 2, abstr 6059)
Link: http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6059?sid=3d6669d4-15f7-4166-a176-369535edacdc

Year: 2009
Title: Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF
Authors: Cheang M;Chia SK;Tu D;Jiang S;Shepherd LE;Pritchard KI;Nielsen TO;
Reference: Journal of Clinical Oncology 2009 May 29; 27 (15s Part 1, abstr 519)
Link: http://meetinglibrary.asco.org/content/35150-65

Year: 2009
Title: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy
Authors: O'Malley FP;Chia S;Tu D;Shepherd LE;Levine MN;Bramwell VH;Andrulis IL;Pritchard KI;
Reference: Journal of the National Cancer Institute 2009 May 6 ; 101 (9)
Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2677575/?report=abstract&tool=pmcentrez

Year: 2011
Title: Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial
Authors: O'Malley FP;Chia S;Tu D;Shepherd LE;Levine MN;Huntsman D;Bramwell VH;Andrulis IL;Pritchard KI;
Reference: Breast Cancer Research and Treatment 2011 Jul 1 ; 128 (2)
Link: http://dx.doi.org/10.1007/s10549-011-1511-5

Year: 2015
Title: Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also
Authors: Bartlett JMS;McConkey CC;Munro AF;Desmedt C;Dunn JA;Larsimont DP;O'Malley FP;Cameron DA;Earl HM;Poole CJ;Shepherd LE;Cardoso F;Jensen MB;Caldas C;Twelves CJ;Rea DW;Ejlertsen B;Di Leo A;Pritchard KI;
Reference: Journal of Clinical Oncology 2015 May 20; 33 (15)
Link: http://jco.ascopubs.org/content/33/15/1680.abstract

Year: 2018
Title: Basal biomarkers Nestin and INPP4b accurately identify intrinsic breast cancer subtype and predict benefit from anthracycline vs. non-anthracycline based treatment in the CCTG MA.5 phase III randomized clinical trial
Authors: Asleh K;Gao DD;Tu D;Shepherd L;Levine MN;Pritchard K;Nielsen T;
Reference: Laboratory Investigation 2018 Mar 17; 98 (suppl 1)
Link:

Inventory
Hide Tissue Samples

Disease Site	Trial Code	Patients Accrued	Patients - Blocks	Patients - Slides	Patients - Blocks and/or Slides
BREAST	MA5	716	599	671	677

Hide TMA Samples

(Core size is 0.6 mm)

Disease Site	Trial Code	Patients Accrued	TMA Blocks	Patients on TMA Blocks
BREAST	MA5	716	9	597

Hide Fluid Samples

Disease Site	Trial Code	Patients Accrued	Patients - Whole Blood	Patients - Cellular Component of Blood	Patients - DNA extracted from Blood	Patients - RNA extracted from Blood	Patients - Plasma	Patients - Serum	Patients - Urine	Patients - Buccal
BREAST	MA5	716	0	0	0	0	0	0	0	0